CC analyst estimates
Chemours (CC) analyst ratings, the average price target and its range, and every firm's latest call.
CC analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 20, 2026 | Truist Financial | Chemours price target lowered to $20 from $24 at Truist | $20.00 |
| Oct 13, 2026 | RBC Capital | RBC Capital Downgrades Chemours (CC) to Sector Perform | $14.00 |
| Oct 12, 2026 | Barclays | Chemours initiated with an Equal Weight at Barclays | $16.00 |
| Oct 9, 2026 | Goldman Sachs | Chemours (CC) PT Lowered to $16 at Goldman Sachs | $16.00 |
| Oct 5, 2026 | UBS | Chemours price target lowered to $16 from $18 at UBS | $16.00 |
| Aug 13, 2026 | Goldman Sachs | Chemours price target lowered to $17 from $19 at Goldman Sachs | $17.00 |
| Aug 13, 2026 | BMO Capital | Chemours price target lowered to $18 from $26 at BMO Capital | $18.00 |
| Aug 10, 2026 | UBS | UBS Downgrades Chemours (CC) to Neutral | $18.00 |
| Aug 10, 2026 | Morgan Stanley | Chemours price target lowered to $18 from $21 at Morgan Stanley | $18.00 |
| Aug 6, 2026 | RBC Capital | Chemours price target lowered to $22 from $26 at RBC Capital | $22.00 |
| Aug 5, 2026 | Mizuho Securities | Chemours price target lowered to $22 from $25 at Mizuho | $22.00 |
| May 13, 2026 | Alembic Global | Chemours price target raised to $30 from $24 at Alembic Global | $30.00 |
| May 11, 2026 | RBC Capital | Chemours price target raised to $29 from $26 at RBC Capital | $29.00 |
| May 11, 2026 | Morgan Stanley | Chemours price target raised to $21 from $17 at Morgan Stanley | $21.00 |
| May 8, 2026 | UBS | Chemours price target raised to $30 from $29 at UBS | $30.00 |
- 9 firms rate CC: 3 buy, 6 hold, 0 sell.
- The average price target is $18.89 from 9 analysts, from $14.00 to $30.00.
Updated 2026-11-02 23:10 UTC